FDA accepts Enzychem’s IND for trial of Covid-19 treatment candidate
The acceptance of IND will allow Enzychem to assess EC-18 in a phase 2 clinical study in patients with ARDS due to Covid-19. The EC-18 is originally obtained
According to the company, SAB-185 is a fully-human, specifically targeted, and broadly neutralising polyclonal antibody therapeutic candidate. Besides potentially treating Covid-19 patients, the drug candidate can provide protective